The relative contributions of type I and type II insulinlike growth factor (IGF) receptors and IGF carrier proteins to the binding of IGF
Introduction
The insulinlike growth factors (IGFs),' IGF-I and IGF-II, are plasma polypeptides chemically related to insulin and possessing Dr. Katsoyannis is a member ofthe Department of Biochemistry, Mount Sinai School of Medicine ofthe City University ofNew York, New York 10029.
1. Abbreviations used in this paper: HBB, Hepes binding buffer; IGF, insulinlike growth factor; MEM, minimal essential medium; MSA, multiplication-stimulating activity; PEG, polyethylene glycol.
The Journal of Clinical Investigation, Inc. Volume 77, February 1986, 602-613 mitogenic activity (1) . They exert their biological effects by interacting with specific IGF receptors on the surface oftarget cells (2) (3) (4) (5) (6) . Two subtypes ofIGF receptors have been identified. Type I IGF receptors are structurally homologous to insulin receptors, with disulfide-linked a-subunits (Mr -130,000) that bind the polypeptides and ,8-subunits (Mr -90,000-100,000) that have intrinsic tyrosine kinase activity. Type I receptors typically have higher affinity for IGF-I than IGF-II, and also bind insulin with lower affinity. By contrast, type II receptors consist of a single Mr 260,000 protein that is not disulfide-linked to other mem- brane proteins and appears to lack tyrosine kinase activity. Type II IGF receptors bind IGF-II in preference to IGF-I, and do not bind insulin.
Because IGF-I and IGF-II bind to both type I and type II IGF receptors and also cross-react with insulin receptors, either of these three receptors might mediate their biological actions (5, 6) . From dose-response curves and experiments using antireceptor antibodies to selectively block insulin receptors, it has been possible to identify IGF-stimulated functions that are mediated by IGF receptors rather than by insulin receptors (5, 7) . It has been more difficult to resolve whether these effects are mediated by type I, type II, or both receptors. Some cells (e.g., chick embryo fibroblasts) only possess type I IGF receptors (2, 8) , so it is quite likely that in these cells the type I receptor mediates IGF-stimulated DNA synthesis. Whether the type II receptor mediates the same or different functions as the type I receptor, or indeed whether it possesses any biological functions (9) (2, (12) (13) (14) . Moreover, '25I-IGF-I bound to human fibroblast monolayers could be chemically cross-linked to the a-subunit of the type I receptor; formation of this complex was inhibited in the presence of high concentrations of insulin (14) . However, in these and similar crosslinking experiments, we were surprised to note that the total radioactivity bound to the fibroblast monolayer was inhibited by IGF-I but not by insulin (Kasuga, M., and M. M. Rechler, unpublished results) . This specificity suggested that the predominant IGF-I binding in intact fibroblast monolayers was not to a type I receptor, but rather to type II IGF receptors and/or to IGF carrier proteins, because neither of these molecules bind insulin. Indeed, a labeled protein ofappropriate molecular weight for an IGF-I-carrier protein complex had been observed on the cross-linking gel described by Rechler (14) . Evidence from our laboratory and others suggested that both potential binding macromolecules were present in human fibroblast cultures ( (20) .
i: See DeVroede et al. (19) . § Relative potency: IGF-I > AiDWjin-BIGF., (19) .
A27 insulin (21) and Aj,,-BGF X (22) (23) .
'25I-IGF-I (sp act 40-250 Ci/g) and '25I-MSA III-2 (sp act Ci/g) were prepared by a modified chloramine T procedure (2, 13 Cultures were fed at day 3, and used for assays 3-5 d later (final cell density 40,000-80,000 cells/cm2).
'251-IGF-I binding was performed as described by Rosenfeld and Dollar (17) . The culture medium was aspirated and the monolayer washed with PBS and pH 8.0 Hepes binding buffer (HBB) (118 mM NaCl; 5 mM KCI; 1.2 mM MgS04; 8.8 mM dextrose; 100 mM Hepes; albumin [Sigma Chemical Co., radioimmunoassay grade], 10 mg/ml). Monolayers were incubated with luI-IGF-I (-250 pg/ml) and various concentrations of unlabeled peptides in HBB for 4-5 h at 15°C in a final volume of 2 ml per 60-mm dish, 0.8 ml per 35-mm well, and 0.5 ml per 22-mm well. At the end of the incubation, the medium was aspirated and the monolayers were washed with ice cold Hanks' buffer or PBS, solubilized in 1.5 ml of I N NaOH, and counted in a Beckman Instruments, Inc. (Palo Alto, CA) gamma counter with 75% efficiency.
Binding ofIGF-I to fibroblast monolayers cultivated in serum-free media. Fibroblasts were plated at a density of 30,000-40,000 cells/cm2 in Dulbecco's modified Eagle's medium-0.2% fetal calfserum in 60-mm dishes, 35-mm wells of six-well tissue culture plates, or 22-mm wells of 12-well tissue culture plates, and were used within 3 d after plating. In some experiments, cells were washed after 48 h and the incubation medium was changed to Eagle's MEM containing I mg/ml albumin for the final 24 h before use. '"I-IGF-I binding was performed as described above.
Binding ofIGF-I to human fibroblasts in suspension. The binding assay was carried out as published previously (13) . Briefly, fibroblasts were plated into 100-mm plastic dishes in Eagle's MEM containing 20% fetal calf serum, fed till confluency, and used 6-7 d after the last feeding. Fibroblasts were detached from the monolayer by washing with PBS without Ca"+ and Mg", followed by incubation for 3-5 min at 370C with 0.01% Trypsin-0.5 mM EDTA (Trypsin, 3,100 Na-benzoyl-L-arginine ethyl ester U/mg, Worthington Biochemical Corp., Freehold, NJ). The reaction was terminated by adding an equal volume of0.02% soybean trypsin inhibitor (Sigma Chemical Co., St. Louis, MO). The cells were collected, washed in Hepes binding buffer, sedimented, and resuspended in HBB. The incubation mixture consisted of 1251I-labeled IGF-I, the indicated concentrations of unlabeled peptides and 1-2 X 106 cells in a total volume of0.5 ml. After 3-4 h ofincubation at 15'C, 0.2-ml aliquots were pipetted in duplicate onto ice-cold buffer (0.2 ml of HBB). The tubes were centrifuged in a Beckman microfuge for 1 min and the supernate was aspirated. The tips containing the cell pellets were excised and the associated radioactivity was quantitated in a gamma counter.
Precipitation ofbinding assay supernate with polyethylene glycol. In some experiments, at the end ofthe binding incubation, the supernatant was recovered and incubated with polyethylene glycol (PEG) to identify 1251-IGF-I bound to macromolecular components (24) . To 0.5 ml of medium was added 0.5 ml ofhuman ey-globulin (2 mg/ml; Pentex, Miles Laboratories, Inc., Elkhart, IN) and 1 ml of 25% (wt/vol) PEG (6,000-8,000), and the mixture was incubated on ice for 15 min. After centrifugation at 3,000 rpm for 20 min at 40C in a Beckman TJ6 centrifuge, the supernate was aspirated and the precipitated radioactivity quantitated in a Beckman gamma counter. Results were corrected for the "blank," i.e., the radioactivity precipitated by PEG-y-globulin from the same amount of radioactive ligand in binding buffer that had not been incubated with cells. Typically, this represented 10-15% of the input radioactivity. Competitive binding protein assay. IGF-binding macromolecules in media conditioned by 5 h of incubation with fibroblast monolayers at 15°C in binding assay buffer also were examined in a direct binding assay using '251-labeled MSA (equivalent to rat IGF-II). Aliquots of media were incubated with 1251I-MSA III-2 and the indicated concentrations of unlabeled peptides in 0.4 ml of PBS containing 2 mg/ml fatty acid-free bovine serum albumin (Sigma Chemical Co.) overnight at 4°C. Tracer MSA not complexed to binding protein was removed by adsorption with activated charcoal as previously described (19, 25) . Complexes of 125I-MSA III-2 with carrier protein remained in the charcoal supernate and were quantitated. Radioactivity in the charcoal supernate in the absence of added carrier protein has been subtracted from each point.
251I-IGF-
IGF-I binding to detergent-solubilized monolayer cultures. Solubilization of fibroblasts with Triton X-100 was performed according to Cuatrecasas (26) . Each 22-mm well was washed with PBS and HBB, and stopped after S h at 150C (or 18 h at 40C) by adding 0.5 ml of -y-globulin and I ml of25% PEG; the mixture was kept on ice for 15 min, centrifuged (20 min, 3,000 rpm) and radioactivity in the precipitate quantitated. All values were corrected for the amount of radioactivity that is precipitated by y-globulin and PEG in the absence of solubilized cells.
In some experiments (as specified), a solubilization buffer (modified from Reference 27) containing 1% (wt/vol) Triton X-100 in 150 mM NaCl, 5 inhibition at~-550 ng/ml and -90% inhibition at 10 ,ug/ml. A specificity profile consistent with binding to a type I receptor also was observed in fibroblasts grown in serum-free medium and studied after suspension (data not shown).
Markedly different results were obtained when binding was performed in situ on fibroblasts cultivated in serum-containing medium ( Fig. 1 A) . Binding of tracer IGF-I in the presence of different concentrations ofunlabeled IGF-I gave a biphasic curve: at lower concentrations ofIGF-I (<10 ng/ml), binding increased to a variable maximum (105-250% of control), whereas dosedependent inhibition was observed at IGF-I concentrations from 10 ng/ml to 1 Ag/ml. Insulin gave a partial inhibition at high concentration (-30% at 10 Ag/ml), and did not increase IGF-I tracer binding at lower concentrations (0.1 and 1 ,ug/ml). The increased binding at low concentrations of IGF-I was observed with cells grown under different cultivation conditions-in fetal calf serum obtained from two sources, on culture plates of different size (22, 35, or 60 mm) obtained from different sources, and with different feeding schedules (zero, one, or two feedings). The two points with highest binding were obtained with fibroblasts plated in 60-mm dishes, and fed twice with media containing serum from Reheis Chemical Co. The relative contributions of these culture conditions to the increased binding have not been determined.
Binding of IGF-I to cell monolayers also was examined in cells plated in serum-poor medium (0.2% fetal calf serum) and changed to serum-free medium prior to assay (Fig. 1 B) . Under these conditions, unlabeled IGF-I at low concentration increased tracer IGF-I binding to a modest extent (-1 15% of control) in only 2 of 12 experiments, and did not increase binding in the other 10 experiments. Insulin again gave negligible inhibition of binding (-10%) at 10 ,ug/ml.
The different effects ofinsulin on IGF-I binding to suspended cells and in situ suggested that, although tracer IGF-I bound predominantly to a type I IGF receptor in suspended cells, binding to this receptor constituted a minor portion of total binding to cell monolayers irrespective of whether the cells had been grown in serum-containing or serum-free media. Moreover, the surprising increase in tracer IGF-I binding to fibroblast monolayers, especially in cells grown in the presence of serum, was not observed when binding was performed with suspended fibroblasts.
Inhibition oftracer binding to suspended fibroblasts and to fibroblast monolayers by insulin-IGF-I hybrid molecules. In an attempt to clarify the nature of the binding sites for IGF-I in cell monolayers, binding inhibition studies were performed using insulin-IGF hybrid molecules (Fig. 2) . The three hybrid molecules gave extensive dose-dependent inhibition of tracer IGF-I binding to suspended fibroblasts ( (20) . Dramatically different results were observed when IGF-I tracer binding to fibroblast monolayers was examined in the presence of the hybrid molecules containing BIGF-I. With cells cultivated in serum-containing medium (Fig. 2 A) , 1251-IGF-I binding in the presence of the hybrid molecules gave a more pronounced biphasic curve than that observed with unlabeled IGF-I. Whereas unlabeled IGF-I modestly increased IGF-I tracer binding at concentrations of 1-5 ng/ml (reaching a maximum of 1 2% ofcontrol), the BIGF-I hybrid molecules at concentrations of 10-100 ng/ml increased IGF-I binding to a greater extent, reaching maxima of 140% and 180% of control. At concentrations from 100 ng/ml to 10 ,g/ml, the hybrid molecules gave dose-dependent but partial inhibition ofbinding (i.e., <30% inhibition of the binding observed with IGF-I tracer alone).
The increased binding of IGF-I tracer in the presence of optimal concentrations of B-IGF-I hybrid does not represent protection ofthe tracer against proteolysis. IGF-I tracer recovered from th supernate after 5 h ofincubation with fibroblast monolayers in the absence or presence ofunlabeled peptide was >95% precipitable by 10% trichloroacetic acid, indicating that the tracer had not been degraded to smaller fragments during the binding incubation.
Qualitatively similar but quantitatively smaller increases were observed in tracer IGF-I binding to monolayers incubated in serum-free media (Fig. 2 B) . The BIGF-I-containing hybrids increased tracer IGF-I binding to a maximum of 115% of control binding at -100 ng/ml, and gave <20% inhibition of binding at 10 jtg/ml. Fig. 3 demonstrates that the specificity of inhibition oftracer binding by different unlabeled peptides to human fibroblast monolayers cultivated in serum-free media was the same whether MSA 111-2 (rat IGF-II) or IGF-I was used as radioligand. With either radioligand, unlabeled IGF-I and IGF-II gave dose-depenent inhibition, with IGF-II two to fourtimes more potentthan IGF-I. Insulin gave only 5-15% inhibition of binding at high concentrations (10 ,ug/ml). The BIGF-I hybrid molecules gave a biphasic curve, with tracer binding increasing at lower concentrations of hybrid (500-1,000 ng/ml) to -120% of control, followed by a decrease to 95-100% of control at 10 sg/ml. These results indicate that '25I-IGF-I and '25I-MSA III-2 bind to the same or similar sites on fibroblast monolayers cultivated in serum-free medium. Because this binding is not inhibited by the B-IGF-I hybrid molecules or insulin at high concentrations, 15 'C under standard binding assay conditions, and binding to the cell monolayers was determined. In addition, at the end ofthe incubation, the media were recovered and incubated with 12.5% PEG in the presence of yglobulin carrier to precipitate higher molecular weight complexes. PEG precipitated 1.5% of the input radioactivity from the incubation media, contrasted with only 3.6% that was bound to the cells (Fig. 4 A) .
In a parallel set of cultures, fibroblast monolayers were preincubated in binding buffer for 5 h at 15'C, after which the media were aspirated and the cells incubated with '25I-IGF-I in fresh binding buffer (5 h, 150C); binding to cells and to PEGprecipitable proteins in the media was determined (Fig. 4 A (Table II) . Tracer IGF-I binding to the solubilized preparations was inhibited by unlabeled IGF-I and by BIGF-I hybrid molecules, but not by insulin or A27 insulin (Fig. 8 A) , a specificity consistent with the predominant binding molcule being an IGF carrier protein.
After preincubation of fibroblast monolayers in binding buffer for 5 h at 1 5'C, binding of tracer IGF-I to the monolayer increased and binding to carrier proteins released to the media decreased (Fig. 4) Figure 7 . IGF carrier protein is released to the incubation media by fibroblast monolayers but not by suspended fibroblasts. Fibroblasts were plated in 100-mm dishes and grown to confluence in media containing 20% fetal calf serum as described in Methods. Cells from one dish were suspended with trypsin-EDTA, washed, and incubated in HBB for 5 h at 150C (five tubes, 0.5 ml/tube). A second dish was washed and incubated with 2.5 ml of HBB at the same time. Aliquots of supernatant media from the suspension and monolayer incubations were examined for presence of IGF carrier proteins by incubation with '25I-IGF-I, and separation of IGF-carrier protein complexes using activated charcoal as described in Methods. A blank value (i.e., radioactivity in the charcoal supernate in the absence of added carrier protein) of 6.5% of input radioactivity has been subtracted. The percent input '251-IGF-I radioactivity specifically bound is plotted against the microliters of supernate from fibroblast monolayers (-) or suspended fibroblasts (o) added to the incubation. Incubation of '25I-IGF-I with 100 ul of supernate from the fibroblast monolayer incubation in the presence of excess unlabeled IGF-I completely abolished the specific binding to the carrier protein (not shown).
that even though appreciable quantities of carrier protein are released from the monolayer to the media during preincubation, even greater amounts of carrier protein remain associated with the cell monolayer, possibly in internal or cryptic sites.
Quite different results were obtained when IGF-I binding was examined using Triton extracts of fibroblasts that had been maintained in serum-poor media. IGF-I tracer binding to solubilized fibroblast extracts was only 77% (range 53-113%) of the binding observed to intact serum-poor monolayers (Table  II) . IGF-I binding to these solubilized extracts was inhibited by low concentrations of unlabeled IGF-I (ED50 1 ng/ml), inhibited -80% by BIGF-I hybrid molecules at 10 Ag/ml, and -50% inhibited by insulin at 10 Atg/ml (Fig. 8 B) . We interpret the fraction of binding that is inhibitable by both the hybrid molecules and insulin as binding to type I IGF receptors, whereas that fraction ofthe hybrid-inhibitable binding that is not inhibited by insulin is thought to represent binding to IGF carrier proteins.
It is of interest that virtually all of the tracer IGF-I binding to solubilized extracts offibroblasts cultivated in serum or serum- Fibroblasts were grown in 22-mm wells in Eagle's MEM containing 20% or 0.2% fetal calf serum. '25_-IGF-I binding to cell monolayers was determined. Replicate culture wells were solubilized with Triton X-100, and '251-IGF-I binding to soluble proteins determined by precipitation with PEG--y-globulin (and corrected for tracer binding to 0.1% Triton X-100 without cells). Cell numbers were -300,000 (20% serum) and -160,000 (0.2% serum), except that -250,000 cells were present at both serum concentrations in experiment 3.
* Percent input 1251-IGF-I bound to cell monolayers (per 22-mm well). * Percent input '25I-IGF-I bound to proteins solubilized from the 22-mm well by Triton X-100. § Ratio of radioactivity bound to Triton-solubilized extract + radioactivity bound to cell monolayer.
free media was inhibited in the presence of BIGF-I hybrid molecules. This suggests that binding to type II IGF receptors was not detected in the Triton-solubilized extracts, most likely because Triton failed to solubilize or inactivated the type H receptor. Support for this interpretation comes from the observation that a different solubilization buffer (TES), containing 1% Triton X-100, 5 mM EDTA, 1% (wt/vol) sodium deoxycholate, ±2% N-octylglucoside effectively solubilized type II IGF receptors and carrier proteins, but not type I IGF receptors (results not shown). Fibroblasts cultivated in serum-free media were extracted with Triton X-100 or TES buffer. IGF-binding to the TES extracts was -140% of that to the Triton extracts. Binding to the TES extracts was not significantly inhibited by 10 gg/ml of insulin (indicating that type I IGF receptors were not present), and was only 50-70% inhibited by 10 Ag/ml of BIGF-I hybrid (suggesting that both IGF carrier proteins and type II receptors were present).
Discussion
Type I and type II IGF receptors and IGF carrier proteins differ in their ability to bind insulin and hybrid molecules containing the A chain of insulin and the B domain of IGF-I (19) . In the present study, we have used these hybrid molecules in competitive binding studies to differentiate the binding sites for IGF-I on cultured human fibroblasts studied after suspension and as monolayer cultures.
Binding of IGF-I tracer to suspended fibroblasts is inhibited by insulin and by B-IGF-I hybrids, a specificity similar to that observed for the chick embryo fibroblast type I receptor (20) and confirming that IGF-I binds predominantly to a type I IGF receptor (2, 12-14) . By contrast, IGF-I binding to fibroblast monolayers is only minimally inhibited by high concentrations The preceding results demonstrate qualitatively that the concentration of unsaturated binding sites for IGF-I on IGF carrier proteins in the incubation media correlates inversely with the magnitude of IGF-I tracer binding to the fibroblast monolayers. The question remained whether the number of possible IGF-I binding sites in the media is sufficient to account quantitatively for the increase in free IGF-I tracer required to cause the observed increase in cell-associated radioactivity. For example, to account for a twofold increase in cell-associated radioactivity upon addition of optimal concentrations of B-IGF-I hybrid, it would be necessary that half ofthe input IGF-I tracer be bound to sites in the media in the absence of the hybrid. Occupancy of the media sites by B-IGF-I hybrid would double the "free" IGF-I tracer available to bind to the cell monolayer. In the experiments presented, <15% of the input radioactivity was precipitated from the incubation medium by 12.5% PEG.
However, under these conditions only -25% of the '251I-IGF-I- (16) . Moreover, protein synthesis is decreased in fibroblasts maintained in serum-free media compared to serum-containing media (Romanus, J. A., and M. M. Rechler, unpublished results). Thus, although we favor the interpretation that the carrier protein released to the media during the binding incubation with fibroblast monolayers is synthesized de novo by the fibroblasts, we cannot exclude the possibility that it represents carrier protein sequestered from the fetal calf serum. 4 IGF carrier proteins appear to be present in fibroblast monolayers in both readily releasable and slowly releasable (internal) pools. Carrier proteins are readily released from the cells to the media after a 5-h incubation at 150C in binding buffer. They also are removed/inactivated by the extensive wash procedure and trypsin treatment used to suspend cells from the monolayer.3 However, considerable quantities of carrier proteins also appear to be present intracellularly, because they are liberated by extraction offibroblast monolayers with Triton X-100 even after 5 h of preincubation in buffer.
Although our model requires that IGF carrier proteins be present in the media at the end ofthe binding incubation, further studies are required to determine when during the incubation the carrier proteins are released from the cell and when they interact with IGF-I tracer. Carrier proteins are not present in the media at the start of the incubation. (17) reported that somatomedin C/IGF-I tracer binding to fibroblast monolayers was inhibited in a simple dose-response curve by IGF-I, less potently by IGF-II, and 60% inhibited by high concentrations of insulin, a specificity consistent with predominant binding to a type I IGF receptor. These studies used cultures established from foreskin of a single newborn donor 4. Carrier proteins continue to be released to both incubation and culture media even after prolonged cultivation in serum-free media. Fibroblast monolayers were grown in serum-containing media, washed, and incubated in Hepes binding buffer (5 h, 15'C), and the incubation media recovered (as described in Fig. 4 B) . The media was replaced with Eagle's MEM for 72 h at 37°C, the media were collected, and a second 5-h incubation (5 h, 1 5°C) in fresh Hepes buffer was performed. The 72-h-37°C-MEM and 5-h-I 5°C-Hepes binding buffer incubations were repeated two additional times. The four sequential 5- (instead of forearm skin of 18-20-year-old volunteers). It is unclear whether somatomedin C purified in their laboratory or IGF-I obtained from Humbel was used as radioligand.5 Other potential variables (growth medium, feeding schedule, cell density) do not appear to be a factor, because our most pronounced biphasic binding curves were observed in experiments performed using their conditions (Fig. 1 A) . Although the same authors also described somatomedin C binding to fibroblast monolayers established from adult forearm skin (28), they did not comment on whether insulin inhibits this binding. Thus it is not possible to determine whether this binding also was to a type I IGF receptor.
Recent results using antireceptor antibodies specific for type I IGF receptors suggest that the IGFs stimulate DNA synthesis in cultured human fibroblasts via the type I IGF receptor (29) . It is curious that the type I receptors appear to be masked or in a cryptic state in fibroblast monolayers, requiring suspension of the cells before they become the predominant binding site for IGF-I. IGF carrier proteins are synthesized by cultured fibroblasts, accumulate intracellularly, and are released to the media. IGF-I binding to carrier proteins in the media and possibly on the cell surface profoundly alters IGF-I binding to IGF receptors on the fibroblast monolayer. These results suggest that carrier proteins may play an important regulatory role in IGF-I binding and action.
